First Turn Management LLC Has $51.41 Million Stake in Abivax SA Sponsored ADR $ABVX

First Turn Management LLC boosted its holdings in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 30.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 381,233 shares of the company’s stock after purchasing an additional 89,413 shares during the period. Abivax makes up 5.9% of First Turn Management LLC’s portfolio, making the stock its largest position. First Turn Management LLC owned 0.48% of Abivax worth $51,411,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its stake in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares during the last quarter. WPG Advisers LLC lifted its stake in Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after purchasing an additional 253 shares during the last quarter. Union Bancaire Privee UBP SA bought a new stake in Abivax in the fourth quarter worth $67,000. Finally, Assetmark Inc. bought a new stake in Abivax in the fourth quarter worth $84,000. 47.91% of the stock is owned by institutional investors.

Abivax Trading Down 4.3%

Shares of NASDAQ:ABVX opened at $96.55 on Friday. The company has a market cap of $7.69 billion, a price-to-earnings ratio of -18.53 and a beta of 0.69. The company has a 50-day moving average price of $116.01 and a 200-day moving average price of $119.12. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.94) by $0.23. The firm had revenue of $1.56 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Wall Street Zen raised shares of Abivax from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research note on Thursday, April 9th. Barclays upped their price objective on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Finally, BTIG Research reaffirmed a “buy” rating and set a $150.00 price objective on shares of Abivax in a research note on Tuesday, June 2nd. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Abivax has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.